Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Layer JV, Cleary JP, Brown AJ, Stevenson KE, Morrow SN, Van Scoyk A, Blasco RB, Karaca E, Meng FL, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, Weinstock DM, Day TA. Parp3 promotes long-range end joining in murine cells. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):10076-10081.
-
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018 02; 16(2):352-363.
-
Fey D, Aksamitiene E, Kiyatkin A, Kholodenko BN. Modeling of Receptor Tyrosine Kinase Signaling: Computational and Experimental Protocols. Methods Mol Biol. 2017; 1636:417-453.
-
Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM. Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology. 2016; 91(6):348-353.
-
Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol. 2015 Jun 11; 8:66.
-
Dang H, Steinway SN, Ding W, Rountree CB. Induction of tumor initiation is dependent on CD44s in c-Met? hepatocellular carcinoma. BMC Cancer. 2015 Mar 21; 15:161.
-
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94.
-
Park IK, Trotta R, Yu J, Caligiuri MA. Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. Eur J Immunol. 2013 Oct; 43(10):2750-5.
-
Sweeny L, Zimmermann TM, Liu Z, Rosenthal EL. Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts. Oral Oncol. 2012 Dec; 48(12):1242-9.
-
Aplin AE. Axl of evil? J Invest Dermatol. 2011 Dec; 131(12):2343-5.